Reuters on MSN1mon
Biopharma Industry Eyes 2025 Bounceback, Grapples With Uncertainty Over Trump ReturnSAN FRANCISCO (Reuters) - The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback